ChromaDex to Present at the 3rd Annual Bernstein Consumer Summit on December 8, 2016
December 01 2016 - 5:30AM
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health,
wellness and nutritional ingredients, that creates science-based
solutions for dietary supplement, food and beverage, skin care,
sports nutrition, and pharmaceutical products, announced today that
its Chief Executive Officer and Founder, Frank Jaksch, will present
at the 3rd Annual Bernstein Consumer Summit. The investor summit
will be held on Dec. 7-8, 2016 at the New York Hilton Midtown in
New York, N.Y.
Mr. Jaksch is scheduled to present on Thursday, Dec. 8 at 2:50
p.m. Eastern Time. ChromaDex management will also attend one-on-one
meetings with institutional investors throughout the day.
About ChromaDex:ChromaDex leverages its
complementary business units to discover, acquire, develop and
commercialize patented and proprietary ingredient technologies that
address the dietary supplement, food, beverage, skin care and
pharmaceutical markets. In addition to our ingredient technologies
unit, we also have business units focused on natural product fine
chemicals (known as "phytochemicals"), chemistry and analytical
testing services, and product regulatory and safety consulting
(known as Spherix Consulting). As a result of our relationships
with leading universities and research institutions, we are able to
discover and license early stage, IP-backed ingredient
technologies. We then utilize our in-house chemistry, regulatory
and safety consulting business units to develop commercially viable
ingredients. Our ingredient portfolio is backed with clinical and
scientific research, as well as extensive IP protection. Our
portfolio of patented ingredient technologies includes NIAGEN®
nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a
caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and
AnthOrigin™, anthocyanins derived from a domestically-produced,
water-extracted purple corn. To learn more about ChromaDex, please
visit www.ChromaDex.com.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. Actual results may differ materially from those set
forth in this release due to the risks and uncertainties inherent
in ChromaDex's business. More detailed information about ChromaDex
and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended January 2, 2016,
ChromaDex's Quarter Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Public Relations Contact:
Breah Ostendorf
Director of Marketing
949-537-4103
breaho@chromadex.com
ChromaDex Investor Relations Contact:
Andrew Johnson
Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024